ATE348827T1 - Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten - Google Patents

Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten

Info

Publication number
ATE348827T1
ATE348827T1 AT02766847T AT02766847T ATE348827T1 AT E348827 T1 ATE348827 T1 AT E348827T1 AT 02766847 T AT02766847 T AT 02766847T AT 02766847 T AT02766847 T AT 02766847T AT E348827 T1 ATE348827 T1 AT E348827T1
Authority
AT
Austria
Prior art keywords
sup
sub
alpha
beta
benzothiophenes
Prior art date
Application number
AT02766847T
Other languages
English (en)
Inventor
Juan Jose Marugan Sanchez
Victor J Marder
Prichard David C U
Beth M Anaclerio
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE348827T1 publication Critical patent/ATE348827T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02766847T 2001-04-27 2002-04-29 Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten ATE348827T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28653201P 2001-04-27 2001-04-27
US32451601P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
ATE348827T1 true ATE348827T1 (de) 2007-01-15

Family

ID=26963889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02766847T ATE348827T1 (de) 2001-04-27 2002-04-29 Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten

Country Status (11)

Country Link
US (3) US6872730B2 (de)
EP (1) EP1390362B1 (de)
JP (1) JP2004527559A (de)
KR (1) KR20040007507A (de)
AT (1) ATE348827T1 (de)
CA (1) CA2445629A1 (de)
DE (1) DE60216910T2 (de)
ES (1) ES2276955T3 (de)
MX (1) MXPA03009716A (de)
NZ (1) NZ528853A (de)
WO (1) WO2002088118A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572690A1 (de) 2002-12-20 2005-09-14 Pharmacia Corporation Thiazolverbindungen als integrinrezeptorantagonisten
PL3050878T3 (pl) 2013-09-24 2022-01-24 Fujifilm Corporation Zawierający atom azotu związek lub jego sól, lub ich kompleks z metalem
KR102506327B1 (ko) * 2016-11-08 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 αV 인테그린 길항제로서의 인다졸 유도체

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
JPH0764841B2 (ja) 1990-10-03 1995-07-12 ファイザー製薬株式会社 インドール誘導体およびその用途
GB9309324D0 (en) 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
HUP9802675A3 (en) 1995-08-14 2000-09-28 Scripps Research Inst Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
CA2250698A1 (en) 1996-03-29 1997-10-09 G.D. Searle & Co. Para-substituted phenylpropanoic acid derivatives as integrin antagonists
CA2256543C (en) 1996-05-31 2010-12-07 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
KR20000022190A (ko) 1996-06-28 2000-04-25 플레믹 크리스티안 인테그린 저해제로서의 페닐알라닌 유도체
WO1998029408A1 (en) 1996-12-26 1998-07-09 Nikken Chemicals Co., Ltd. N-hydroxyurea derivatives and medicinal compositions containing the same
CA2315232A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
GB9814801D0 (en) 1998-07-09 1998-09-09 Univ Strathclyde Integrin dependent cell adhesion inhibitors
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
BR9916536A (pt) 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
DE10006139A1 (de) 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
US20050165036A1 (en) 2005-07-28
US20030018064A1 (en) 2003-01-23
US6872730B2 (en) 2005-03-29
KR20040007507A (ko) 2004-01-24
JP2004527559A (ja) 2004-09-09
DE60216910T2 (de) 2007-10-18
ES2276955T3 (es) 2007-07-01
EP1390362B1 (de) 2006-12-20
EP1390362A1 (de) 2004-02-25
WO2002088118A1 (en) 2002-11-07
CA2445629A1 (en) 2002-11-07
US20050228011A1 (en) 2005-10-13
DE60216910D1 (de) 2007-02-01
MXPA03009716A (es) 2004-03-10
NZ528853A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
ATE530183T1 (de) Substituierte indole und ihre verwendung als integrin-antagonisten
NO20050068L (no) Nye karboksamid-forbindelser med en mch-antagonist-virkning, medikamenter inneholdende disse forbindelsene, og fremgangsmater for fremstilling derav
DZ3263A1 (fr) Antagonistes du recepteur de l'alpha v integrine
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
DE60335911D1 (de) Isochinolinonderivate und deren verwendung als medikamente
ATE236626T1 (de) Integrin antagonist
YU29892A (sh) Postupak za stereoselektivno dobijanje supstituisanih piperidina
DE60121931D1 (de) Chinazolinverbindungen
HRP20041042A2 (hr) Novi supstituirani derivati sulfamata kao antikonvulzivi
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
ATE364605T1 (de) 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
DE502005009201D1 (de) Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen
ATE414090T1 (de) Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit
ES2159717T3 (es) Derivados de acido 5-(piperidinil-1 sustituido en posicion 4)-3-aril-pentanoico como antagonistas de los receptores de taquiquinina.
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
EP1315501A4 (de) Alpha v integrin-rezeptor-antagonisten
ATE348827T1 (de) Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten
DE60327375D1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
DE60326263D1 (de) Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten
DE60042446D1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
DK1534352T3 (da) Implantat til transport og afgivelse af farmakologisk aktive midler såvel som en fremgangsmåde til fremstilling af samme
WO2005092307A3 (en) Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
ATE383343T1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
ATE469146T1 (de) Benzofuranderivate und deren verwendung bei der behandlung von mikrobiellen infektionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties